Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Significance: Emerging evidence indicates patients who benefit from antiangiogenic therapies have improved vessel function. To determine how bevacizumab modulates vessel morphology to improve vessel function we conducted a phase II trial of preoperative bevacizumab followed by bevacizumab combined with chemotherapy in HER2-negative breast cancer patients. Our results suggest that the clinical response to bevacizumab may occur through an increase in the extent of vascular normalization primarily in patients with a high baseline tumor microvessel density. If validated, these observations suggest approaches to improve antiangiogenic therapy and to identify patients likely to benefit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the dose and schedule of anti-VEGF agents might need to be tailored to baseline levels of tumour vascularity78 and/or VEGF.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [78]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,721
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
Fisher, B., Bryant, J., Wolmark, N., Mamounas, E., Brown, A., Fisher, E. R., Wickerham, D. L., Begovic, M., DeCillis, A., Robidoux, A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2672 · Cited by 2,165 · cited 2×
“Breast Cancer Res Treat 125(3):687–696.”
BackgroundWillett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,966 · cited 1×
“Nonetheless, the magnitude of the decrease in IFP was less than that seen in rectal cancer (20, 22), which may indicate that either BC vessels are less sensitive to VEGF blockade or bevacizumab distribution in BC tissue is limited.”
BackgroundSelf-citationBatchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W.-T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P.-J., Zhu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.021 · Cited by 1,769
Self-citationMeasurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
Symmans, W. F., Peintinger, F., Hatzis, C., Rajan, R., Kuerer, H., Valero, V., Assad, L., Poniecka, A., Hennessy, B., Green, M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.6823 · Cited by 1,654
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589 · cited 3×
“, pancreatic ductal adenocarcinoma), strategies that increase perfusion without pruning—targeting alternative angiogenic pathways (46), directly inducing differentiation of intratumoral sources of pericyte progenitors (47), and increasing vessel patency by reducing solid stress (31–33) or enhancing lumen formation (48…”
BackgroundSelf-citationKuerer, H. M., Newman, L. A., Smith, T. L., Ames, F. C., Hunt, K. K., Dhingra, K., Theriault, R. L., Singh, G., Binkley, S. M., Sneige, N., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.460 · Cited by 1,330 · cited 1×
“Moreover, a favorable pathologic response to neoadjuvant therapy is associated with longer diseasefree survival (4, 5).”
BackgroundNeoadjuvant Versus Adjuvant Systemic Treatment in Breast Cancer: A Meta-Analysis
Mauri, D., Pavlidis, N., & Ioannidis, J. P. A. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji021 · Cited by 1,200 · cited 1×
“Moreover, a favorable pathologic response to neoadjuvant therapy is associated with longer diseasefree survival (4, 5).”
BackgroundTong, R. T., Boucher, Y., Kozin, S. V., Winkler, F., Hicklin, D. J., & Jain, R. K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0074 · Cited by 1,189 · cited 1×
“This index is proportional to a reduction in vessel permeability, which is related to high levels of pericyte coverage in preclinical models (39), and an increase in cerebral blood volume, which is indicative of increased MVD.”
BackgroundSelf-citationKinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation
Winkler, F., Kozin, S. V., Tong, R. T., Chae, S.-S., Booth, M. F., Garkavtsev, I., Xu, L., Hicklin, D. J., Fukumura, D., di Tomaso, E., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.011 · Cited by 1,170 · cited 2×
“To our knowledge this is the first clinical evidence of antiangiogenic therapy-induced pericyte recruitment, which has previously only been demonstrated preclinically (18).”
BackgroundSelf-citationHuang, Y., Yuan, J., Righi, E., Kamoun, W. S., Ancukiewicz, M., Nezivar, J., Santosuosso, M., Martin, J. D., Martin, M. R., Vianello, F., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215397109 · Cited by 1,099 · cited 2×
“Although there are no clinical studies investigating the relationship between PCMVD and tumor oxygenation, preclinical studies demonstrated that increased PC-MVD is associated with increased vascular function and oxygenation (37, 38).”
BackgroundSelf-citationChauhan, V. P., Martin, J. D., Liu, H., Lacorre, D. A., Jain, S. R., Kozin, S. V., Stylianopoulos, T., Mousa, A. S., Han, X., Adstamongkonkul, P., et al. (2013) · Nature Communications · doi:10.1038/ncomms3516 · Cited by 1,031
Self-citationSikov, W. M., Berry, D. A., Perou, C. M., Singh, B., Cirrincione, C. T., Tolaney, S. M., Kuzma, C. S., Pluard, T. J., Somlo, G., Port, E. R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.0572 · Cited by 1,013
Self-citationOgston, K. N., Miller, I. D., Payne, S., Hutcheon, A. W., Sarkar, T. K., Smith, I., Schofield, A., & Heys, S. D. (2003) · The Breast · doi:10.1016/s0960-9776(03)00106-1 · Cited by 982
Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors
Stylianopoulos, T., Martin, J. D., Chauhan, V. P., Jain, S. R., Diop-Frimpong, B., Bardeesy, N., Smith, B. L., Ferrone, C. R., Hornicek, F. J., Boucher, Y., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213353109 · Cited by 943
Self-citationMazzone, M., Dettori, D., Leite de Oliveira, R., Loges, S., Schmidt, T., Jonckx, B., Tian, Y.-M., Lanahan, A. A., Pollard, P., Ruiz de Almodovar, C., et al. (2009) · Cell · doi:10.1016/j.cell.2009.01.020 · Cited by 812 · cited 2×
“Changes of sVEGFR1 levels—a factor linked with “vascular normalization” (37) that we proposed as a resistance biomarker to neoadjuvant bevacizumab in rectal cancer (40)— was directly associated with pericyte coverage and inversely associated with response.”
BackgroundRonnov-Jessen, L., Petersen, O. W., & Bissell, M. J. (1996) · Physiological Reviews · doi:10.1152/physrev.1996.76.1.69 · Cited by 793 · cited 1×
“Additionally, a significant fraction of BCs are desmoplastic (29, 30), which might cause vessel compression and reduce the patency of vessels (31–33).”
BackgroundA role for VEGF as a negative regulator of pericyte function and vessel maturation
Greenberg, J. I., Shields, D. J., Barillas, S. G., Acevedo, L. M., Murphy, E., Huang, J., Scheppke, L., Stockmann, C., Johnson, R. S., Angle, N., et al. (2008) · Nature · doi:10.1038/nature07424 · Cited by 629 · cited 1×
“blockade may also promote maturation of nascent vessels through active pericyte recruitment, thereby increasing PC-MVD (17, 18).”
BackgroundJain, R. K., Tong, R. T., & Munn, L. L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4102 · Cited by 612 · cited 1×
“1D), presumably due to a decrease in vascular permeability (19).”
BackgroundSelf-citationClinical management of breast cancer heterogeneity
Zardavas, D., Irrthum, A., Swanton, C., & Piccart, M. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.73 · Cited by 570 · cited 1×
“Discussion BC is a complex disease composed of several biologically distinct subtypes (21).”
BackgroundNeoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
von Minckwitz, G., Eidtmann, H., Rezai, M., Fasching, P. A., Tesch, H., Eggemann, H., Schrader, I., Kittel, K., Hanusch, C., Kreienberg, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1111065 · Cited by 530
Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer
Bear, H. D., Tang, G., Rastogi, P., Geyer, C. E., Robidoux, A., Atkins, J. N., Baez-Diaz, L., Brufsky, A. M., Mehta, R. S., Fehrenbacher, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1111097 · Cited by 461 · cited 1×
“007) but no statistically significant difference in TNBC (9).”
BackgroundCameron, D., Brown, J., Dent, R., Jackisch, C., Mackey, J., Pivot, X., Steger, G. G., Suter, T. M., Toi, M., Parmar, M., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70335-8 · Cited by 432 · cited 1×
“Moreover, two postoperative (adjuvant) trials of bevacizumab, BEATRICE and E5103, demonstrated no improvement in disease-free survival with the addition of bevacizumab to standard anthracycline- and taxane-based chemotherapy (2, 10).”
BackgroundWillett, C. G., Boucher, Y., Duda, D. G., di Tomaso, E., Munn, L. L., Tong, R. T., Kozin, S. V., Petit, L., Jain, R. K., Chung, D. C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.5635 · Cited by 420
Self-citationSorensen, A. G., Batchelor, T. T., Zhang, W.-T., Chen, P.-J., Yeo, P., Wang, M., Jennings, D., Wen, P. Y., Lahdenranta, J., Ancukiewicz, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0814 · Cited by 394 · cited 1×
“Our result of increased PCMVD correlating with tumor regression is consistent with a cediranib study in glioblastoma, which identified a “vascular normalization index” as a measure of the extent of vascular normalization (14).”
ResultSelf-citationBatchelor, T. T., Gerstner, E. R., Emblem, K. E., Duda, D. G., Kalpathy-Cramer, J., Snuderl, M., Ancukiewicz, M., Polaskova, P., Pinho, M. C., Jennings, D., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318022110 · Cited by 340 · cited 1×
“Similar imaging studies of cediranib in glioblastoma also linked improved survival with treatment-induced increases in perfusion and oxygenation (11, 15).”
BackgroundSelf-citationMarkers of Response for the Antiangiogenic Agent Bevacizumab
Lambrechts, D., Lenz, H.-J., de Haas, S., Carmeliet, P., & Scherer, S. J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.2762 · Cited by 332 · cited 1×
“However, there are no structural features of tumor vessels that can be used to predict the response (16), and the vascular changes induced by AAs to increase vessel function remain unclear.”
BackgroundSorensen, A. G., Emblem, K. E., Polaskova, P., Jennings, D., Kim, H., Ancukiewicz, M., Wang, M., Wen, P. Y., Ivy, P., Batchelor, T. T., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2464 · Cited by 295 · cited 1×
“Similar imaging studies of cediranib in glioblastoma also linked improved survival with treatment-induced increases in perfusion and oxygenation (11, 15).”
BackgroundSelf-citationde Kruijf, E. M., van Nes, J. G. H., van de Velde, C. J. H., Putter, H., Smit, V. T. H. B. M., Liefers, G. J., Kuppen, P. J. K., Tollenaar, R. A. E. M., & Mesker, W. E. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0855-6 · Cited by 283 · cited 1×
“Additionally, a significant fraction of BCs are desmoplastic (29, 30), which might cause vessel compression and reduce the patency of vessels (31–33).”
Background(1992) · PubMed · Cited by 252
Self-citation(1991) · PubMed · Cited by 220
Self-citationChauhan, V. P., Boucher, Y., Ferrone, C. R., Roberge, S., Martin, J. D., Stylianopoulos, T., Bardeesy, N., DePinho, R. A., Padera, T. P., Munn, L. L., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.06.003 · Cited by 204 · cited 1×
“Proc Natl Acad Sci USA 106(33): 14004–14009.”
Self-citationLambrechts, D., Claes, B., Delmar, P., Reumers, J., Mazzone, M., Yesilyurt, B. T., Devlieger, R., Verslype, C., Tejpar, S., Wildiers, H., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70231-0 · Cited by 187 · cited 1×
“Two phase III randomized trials of bevacizumab have shown that specific VEGFR1 SNPs correlated with high VEGFR1 expression and poor outcome (41).”
BackgroundEarl, H. M., Hiller, L., Dunn, J. A., Blenkinsop, C., Grybowicz, L., Vallier, A.-L., Abraham, J., Thomas, J., Provenzano, E., Hughes-Davies, L., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70137-3 · Cited by 135
Heist, R. S., Duda, D. G., Sahani, D. V., Ancukiewicz, M., Fidias, P., Sequist, L. V., Temel, J. S., Shaw, A. T., Pennell, N. A., Neal, J. W., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424024112 · Cited by 126
Self-citationHypoxia-Inducible Factor 1α Expression as an Intrinsic Marker of Hypoxia
Hutchison, G. J., Valentine, H. R., Loncaster, J. A., Davidson, S. E., Hunter, R. D., Roberts, S. A., Harris, A. L., Stratford, I. J., Price, P. M., & West, C. M. L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0135 · Cited by 125
Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases
Jeong, H.-S., Jones, D., Liao, S., Wattson, D. A., Cui, C. H., Duda, D. G., Willett, C. G., Jain, R. K., & Padera, T. P. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv155 · Cited by 120
Self-citationGoel, S., Gupta, N., Walcott, B. P., Snuderl, M., Kesler, C. T., Kirkpatrick, N. D., Heishi, T., Huang, Y., Martin, J. D., Ager, E., et al. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt164 · Cited by 117 · cited 1×
“, pancreatic ductal adenocarcinoma), strategies that increase perfusion without pruning—targeting alternative angiogenic pathways (46), directly inducing differentiation of intratumoral sources of pericyte progenitors (47), and increasing vessel patency by reducing solid stress (31–33) or enhancing lumen formation (48…”
BackgroundSelf-citationTumor angiogenesis, from foe to friend
Rivera, L. B., & Bergers, G. (2015) · Science · doi:10.1126/science.aad0862 · Cited by 108
Mayer, A., Wree, A., Höckel, M., Leo, C., Pilch, H., & Vaupel, P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3566 · Cited by 101
Duda, D. G., Willett, C. G., Ancukiewicz, M., Tomaso, E., Shah, M., Czito, B. G., Bentley, R., Poleski, M., Lauwers, G. Y., Carroll, M., et al. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-0029 · Cited by 94 · cited 1×
“Changes of sVEGFR1 levels—a factor linked with “vascular normalization” (37) that we proposed as a resistance biomarker to neoadjuvant bevacizumab in rectal cancer (40)— was directly associated with pericyte coverage and inversely associated with response.”
BackgroundSelf-citationYang, S. X., Steinberg, S. M., Nguyen, D., Wu, T. D., Modrusan, Z., & Swain, S. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4762 · Cited by 89
Abraham, S., Scarcia, M., Bagshaw, R. D., McMahon, K., Grant, G., Harvey, T., Yeo, M., Esteves, F. O. G., Thygesen, H. H., Jones, P. F., et al. (2015) · Nature Communications · doi:10.1038/ncomms8286 · Cited by 79 · cited 1×
“, pancreatic ductal adenocarcinoma), strategies that increase perfusion without pruning—targeting alternative angiogenic pathways (46), directly inducing differentiation of intratumoral sources of pericyte progenitors (47), and increasing vessel patency by reducing solid stress (31–33) or enhancing lumen formation (48…”
BackgroundZhu, A. X., Ancukiewicz, M., Supko, J. G., Sahani, D. V., Blaszkowsky, L. S., Meyerhardt, J. A., Abrams, T. A., McCleary, N. J., Bhargava, P., Muzikansky, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3041 · Cited by 73 · cited 1×
“Proc Natl Acad Sci USA 109(43):17561–17566.”
Self-citationLongitudinal and multimodal in vivo imaging of tumor hypoxia and its downstream molecular events
Lehmann, S., Stiehl, D. P., Honer, M., Dominietto, M., Keist, R., Kotevic, I., Wollenick, K., Ametamey, S., Wenger, R. H., & Rudin, M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901194106 · Cited by 63
Vasudev, N. S., Goh, V., Juttla, J. K., Thompson, V. E., Larkin, J., Gore, M. E., Nathan, P., & Reynolds, A. R. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.429 · Cited by 61
Gasparini, G., Torino, F., Ueno, T., Cascinu, S., Troiani, T., Ballestrero, A., Berardi, R., Shishido, J., Yoshizawa, A., Mori, Y., et al. (2012) · Angiogenesis · doi:10.1007/s10456-011-9250-0 · Cited by 56 · cited 1×
“In patients with other tumor types treated with bevacizumab and cytotoxic therapy, correlations between baseline MVD and response have also been documented (24, 25), whereas other studies have found no relationship between MVD or MVD surrogates and response (26, 27).”
ResultMeyerhardt, J. A., Ancukiewicz, M., Abrams, T. A., Schrag, D., Enzinger, P. C., Chan, J. A., Kulke, M. H., Wolpin, B. M., Goldstein, M., Blaszkowsky, L., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038231 · Cited by 48
Self-citationAnti–Vascular Endothelial Growth Factor Therapy in Breast Cancer: Game Over?
Sledge, G. W. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.1298 · Cited by 46 · cited 4×
“In this context, our results also offer a potential explanation for the failure of antiangiogenesis therapy postoperatively (2), because micrometastatic lesions might have very low MVD and lack angiogenesis (28).”
BackgroundInfluentialZhu, Q., Wang, L., Tannenbaum, S. H., Ricci, A., DeFusco, P. A., & Hegde, P. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0456-0 · Cited by 45
Raut, C. P., Boucher, Y., Duda, D. G., Morgan, J. A., Quek, R., Ancukiewicz, M., Lahdenranta, J., Eder, J. P., Demetri, G. D., & Jain, R. K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0026331 · Cited by 42
Self-citationVerstraete, M., Debucquoy, A., Dekervel, J., van Pelt, J. F., Verslype, C., Devos, E., Chiritescu, G., Dumon, K., D’Hoore, A. J. L., Gevaert, O., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.93 · Cited by 32 · cited 2×
“Of note, this high MVD threshold in HRBC is lower than the lowest MVD of all patients assessed in a recent colorectal study (27).”
BackgroundResultChen, S., Liu, Y., Ouyang, Q.-W., Huang, L., Luo, R.-C., & Shao, Z. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3894-0 · Cited by 29
Patenaude, A., Woerher, S., Umlandt, P., Wong, F., Ibrahim, R., Kyle, A. H., Unger, S., Fuller, M., Parker, J., Minchinton, A. I., et al. (2015) · Microvascular Research · doi:10.1016/j.mvr.2015.05.004 · Cited by 16
García‐Foncillas, J., Martinez, P., Lahuerta, A., Llombart‐Cussac, A., Gonzalez, M. G., Gomez, R. M. S., Álvarez, I., Antón, A., Illarramendi, J. J., Juan, A. D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.10512 · Cited by 11
Bevacizumab: the phoenix of breast oncology?
André, F., Deluche, É., & Bonnefoi, H. R. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70201-9 · Cited by 8 · cited 1×
“However, the potential mechanistic link between sufficient MVD and changes in PC-MVD with tumor regression needs to be confirmed through simultaneous biopsies and functional imaging studies in larger clinical studies (45).”
Background
Research works printed but not linked: 1
- D Foernzler Tumor tissue based biomarker analysis in NO16966: A randomized phase III study of first-line bevacizumab in combination with oxaliplatin-based chemotherapy in patients with mCRC. ASCO Gastrointestinal Cancers Symposium (abstr 374). Available at meetinglibrary.asco.org/content/2207-72. (2010).
Cited by
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Self-citationTherapeutic Targeting of the Tumor Microenvironment
Bejarano, L., Jordāo, M. J. C., & Joyce, J. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1808 · Cited by 1,653
“As an alternative, both preclinical and clinical studies indicated that careful dosing of antiangiogenic therapies could favor vessel normalization, resulting in a better patient outcome (226, 227).”
Tumor angiogenesis and vascular normalization: alternative therapeutic targets
Viallard, C., & Larrivée, B. (2017) · Angiogenesis · doi:10.1007/s10456-017-9562-9 · Cited by 1,424
“Careful dosage of VEGF inhibitors can restore levels of angiogenic signals in tumors, leading to decreased permeability by tightening cell–cell junctions and by actively recruiting pericytes, resulting in increased tumor perfusion [103].”
BackgroundAntiangiogenic therapy in oncology: current status and future directions
Jayson, G. C., Kerbel, R., Ellis, L. M., & Harris, A. L. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01088-0 · Cited by 828
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Ramjiawan, R. R., Griffioen, A. W., & Duda, D. G. (2017) · Angiogenesis · doi:10.1007/s10456-017-9552-y · Cited by 672
“Functionally, vascular normalization reduces hypoxia and increases the delivery and efficacy of cytotoxic agents [25, 33, 151].”
Self-citation
Metadata
- Authors
- Tolaney, S. M., Boucher, Y., Duda, D. G., Martin, J. D., Seano, G., Ancukiewicz, M., Barry, W. T., Goel, S., Lahdenrata, J., Isakoff, S. J., Yeh, E. D., Jain, S. R., Golshan, M., Brock, J., Snuderl, M., Winer, E. P., Krop, I. E., & Jain, R. K.
- Affiliations
- Harvard University (US)
- Brigham and Women's Hospital (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2015-11-02
- Volume
- 112
- Issue
- 46
- Pages
- 14325-14330
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC4655544
- OpenAlex
- W1921704765
- Cited by
- 258
- References
- 59
- Citations by year
- 2026: 9 · 2025: 19 · 2024: 17 · 2023: 19 · 2022: 34 · 2021: 33 · 2020: 20 · 2019: 35 · 2018: 21 · 2017: 31 · 2016: 20
- FWCI
- 10.42
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion, other-oa)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
- Funders
- Genentech (Gen24357)
- HHS | NIH | National Cancer Institute (2P50 CA089393-08S2, R01CA098706)
- U.S. Department of Defense (W81XWH-10-1-0016)
- Susan G. Komen for the Cure (PDF14301739)
- Associazione Italiana per la Ricerca sul Cancro (13604)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Keywords
- bevacizumab, breast cancer, neoadjuvant chemotherapy, microvessel density, vascular normalization, interstitial fluid pressure, triple-negative breast cancer, HER2-negative breast cancer, pathological complete response, predictive biomarkers, basal-like breast cancer, hormone receptor-positive breast cancer
- MeSH terms
- Bevacizumab, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Female, Humans, Middle Aged, Neovascularization, Pathologic, Biomarkers, Tumor, Neoadjuvant Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.